Attis Provides an Update on the Status of its Public Securities

via NEWMEDIAWIRE -- Attis Industries Inc. (OTCPink: ATIS) (the “Company” or “Attis”), a diversified innovation and technology holding company, today announced that, effective today, the Nasdaq Capital Market (the “Exchange”), due to the Company’s delinquency in filing its periodic reports, has delisted the Company’s publicly-available securities.  For the immediate future, Attis’ common stock (ATIS) and publicly-traded warrants (ATISW) will trade on the OTCPink Marketplace operated by OTC Markets Group Inc.

Attis is continuing to work tirelessly with its independent accounting firm to bring all of its delinquent filings current.  Once all of the filings have been completed and filed with the Securities and Exchange Commission, and all other listing requirements have been met, the Company plans to immediately begin the reapplication process with the Exchange to elevate Attis’ publicly-available securities back to the Nasdaq stock exchange. 

Attis Industries, Inc. 

Attis Industries Inc. (OTCPink: ATIS) is a diversified innovation and technology holding company focused on developing and building businesses in the healthcare, sustainable materials and renewable fuel markets. We strive to encourage our employees to be entrepreneurs focused on innovation and technology. We will remain dynamic, persistent and motivated to our mission of winning. The growth of our company will rely on our integrity and our vision for the future. Today, each of Attis business sectors provide high growth opportunities. For more information, visit: www.attisind.com

Forward-Looking Statements

Any statements contained in this press release that do not describe historical facts may constitute forward-looking statements as that term is defined in the Private Securities Litigation Reform Act of 1995. You can identify forward-looking statements by words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “plan,” “should,” “would” or similar words. You should consider these statements carefully because they discuss our plans, targets, strategies, prospects and expectations concerning our business, operating results, financial condition and other similar matters. These statements are subject to certain risks, uncertainties, and assumptions, including, but not limited to, risks and uncertainties relating to the Company's ability to develop, market and sell products based on its technology; the expected benefits and efficacy of the Company's products and technology; the availability of substantial additional funding for the Company to continue its operations and to conduct research and development, clinical studies and future product commercialization; and, the Company's business, research, product development, regulatory approval, marketing and distribution plans and strategies; the ability of the Company to execute on a business plan that permits the technologies and innovations businesses to provide sufficient growth, revenue, liquidity and cash flows for sustaining the Company’s go-forward business, and the risks identified and discussed under the caption “Risk Factors” in the Attis Annual Report on Form 10-K for the fiscal year ended December 31, 2017, filed with the Securities and Exchange Commission (the “SEC”) on April 16, 2018 and the other documents Attis files with the SEC from time to time. There will be events in the future, however, that Attis is not able to predict accurately or control. Attis’s actual results may differ materially from the expectations that Attis describes in its forward-looking statements. Factors or events that could cause Attis’s actual results to materially differ may emerge from time to time, and it is not possible for Attis to accurately predict all of them. Any forward-looking statement made by Attis in this press release speaks only as of the date on which Attis makes it. Attis undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by law.

Corporate Investor Relations: 

[e-mail]